Signal active
Investment Firm
Overview
IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and create value out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.
Highlights
2001
Financial Services
101-250
284
57
29
Early Stage Venture, Late Stage Venture, Seed, Private Equity
Venture Capital
Location
Europe
Contact Information
Social
Profile Resume
IP Group, established in 2001 and headquartered in Europe., specializes in Early Stage Venture, Late Stage Venture, Seed, Private Equity investments across Semiconductor, Manufacturing, Developer Platform, Nanotechnology, Sensor, Financial Services, Venture Capital, Finance, Biotechnology, Biopharma. The organization boasts a portfolio of 284 investments, with an average round size of $20.1M and 29 successful exits. Their recent investments include Surrey NanoSystems, Octopus Ventures, Oxford Nanopore Technologies, Top Technology Ventures, Polar OLED. The highest investment round they participated in was $402.4B. Among their most notable exits are Surrey NanoSystems and Octopus Ventures. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
284
10
57
29
Investments
284
Annouced Date | Organization Name | Industry | Money Raised |
---|---|---|---|
Jul 24, 2023 | Crescendo Biologics | Biotechnology | 32.0M |
Nov 27, 2023 | - | - | 100.0M |
Jan 29, 2024 | Enterprise Therapeutics | Health Care | 33.1M |
Mar 14, 2024 | MISSION Therapeutics | Biotechnology | 32.1M |
Exits
29
Funding Timeline
284
1
3
Funding Rounds
284
IP Group has raised 284 rounds. Their latest funding was raised on Mar 14, 2024 from a Series D - MISSION Therapeutics round.
Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
---|---|---|---|---|
Jul 24, 2023 | Venture Round - Crescendo Biologics | - | 32.0M | - |
Nov 27, 2023 | Series B - Oxford Quantum Circuits | - | 100.0M | - |
Jan 29, 2024 | Series B - Enterprise Therapeutics | - | 33.1M | - |
Mar 14, 2024 | Series D - MISSION Therapeutics | - | 32.1M | - |
Investors
1
Investor Name | Lead Investor | Funding Round | Money Raised |
---|---|---|---|
- | Yes | Post-IPO Equity - IP Group | 30.0M |
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
Annouced Date | Fund Name | Money Raised |
---|---|---|
May 10, 2013 | OTPPLESS | 1.0M |
May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.